Renal tuberculosis in an imatinib-treated chronic myeloid leukemia

Imatinib, which inhibits tyrosine kinase activity of Bcr-Abl protein, is a standard form of treatment for chronic myeloid leukemia (CML). Through its immunomodulatory effect it affects T cell function in a number of ways. It inhibits antigen-induced T cell activation and proliferation. Antigen-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandra, Abhilash, Rao, Namrata, Malhotra, Kiran Preet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Nefrologia 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657051/
https://www.ncbi.nlm.nih.gov/pubmed/32353102
http://dx.doi.org/10.1590/2175-8239-JBN-2019-0123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657051/
https://www.ncbi.nlm.nih.gov/pubmed/32353102
http://dx.doi.org/10.1590/2175-8239-JBN-2019-0123

Ejemplares similares